Ayurveda anti-cancer drug to undergo clinical trials

A formula, code-named V2S2 and prepared from hydro-alcoholic extracts of several medicinal plants at the National Institute of Ayurveda (NIA), is set to undergo clinical trials for cancer treatment. 

An agreement has been reached between the National Institute of Ayurveda (NIA) under the Ministry of AYUSH, the Tata Memorial Hospital, Mumbai, the Directorate General, Ayush, Jammu and Kashmir, and AIMIL Pharma for this.

The anti-carcinogenic properties of V2S2 have already been confirmed in laboratory tests. It has also been found to be effective in increasing immunity and inhibiting the growth of cancer cells. This potency of V2S2 comes with no toxicity or with minimum toxicity compared to conventional drugs. 

"This agreement has been signed for formal in-vivo testing. Trials of medicine on animals will be started soon,"  said NIA Vice Chancellor Dr Sanjeev Sharma. Describing the agreement as a milestone in cancer drug research, Dr Sanchit Sharma, Executive Director, AIMIL Pharmaceuticals, expressed confidence that Ayurveda will be able to provide effective cancer treatment options in the next two-three years. 

The initial results of the drug had shown that it increases the immunity of humans and slows down the growth of cancer cells. The next series of tests will be conducted at the Tata Memorial Hospital in Mumbai. Depending on the results, trials on humans will be conducted by the NIA and the J&K Ayush Department. The task of manufacturing the drug has been entrusted to AIMIL Pharmaceuticals.  

Managed by ayurvedamagazine.org

Leave a Comment: